tiprankstipranks
Trending News
More News >
Daiichi Sankyo Company Limited (JP:4568)
:4568

Daiichi Sankyo Company (4568) Price & Analysis

Compare
21 Followers

4568 Stock Chart & Stats

¥3341.00
-¥99.00(-2.29%)
At close: 4:00 PM EST
¥3341.00
-¥99.00(-2.29%)

Bulls Say, Bears Say

Bulls Say
Corporate ConfidenceA recent JPY200Bn-buyback was conducted in defiance of the weak stock price, indicating confidence in the company's corporate value.
Drug DevelopmentAdvancing to Enhertu’s filing for 1L HER2+ BC with strong DB09 interim data shows promising progress in drug development.
FDA ApprovalFDA has approved anticancer candidate Dato-DXd for breast cancer, which is considered a positive surprise by the market.
Bears Say
Disappointing Study DataDaiichi's shares have declined by about 1/3 since the company reported disappointing Ph2 data from the TROPION-Lung01 study.
Stock DeclineDaiichi's shares have declined by about 1/3 since the company reported disappointing data from a lung cancer study.

Daiichi Sankyo Company News

4568 FAQ

What was Daiichi Sankyo Company Limited’s price range in the past 12 months?
Daiichi Sankyo Company Limited lowest stock price was ¥3036.00 and its highest was ¥4564.00 in the past 12 months.
    What is Daiichi Sankyo Company Limited’s market cap?
    Daiichi Sankyo Company Limited’s market cap is ¥6.45T.
      When is Daiichi Sankyo Company Limited’s upcoming earnings report date?
      Daiichi Sankyo Company Limited’s upcoming earnings report date is Jan 30, 2026 which is in 42 days.
        How were Daiichi Sankyo Company Limited’s earnings last quarter?
        Daiichi Sankyo Company Limited released its earnings results on Oct 31, 2025. The company reported ¥24.52 earnings per share for the quarter, missing the consensus estimate of ¥44.829 by -¥20.309.
          Is Daiichi Sankyo Company Limited overvalued?
          According to Wall Street analysts Daiichi Sankyo Company Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Daiichi Sankyo Company Limited pay dividends?
            Daiichi Sankyo Company Limited pays a Semiannually dividend of ¥39 which represents an annual dividend yield of 2.03%. See more information on Daiichi Sankyo Company Limited dividends here
              What is Daiichi Sankyo Company Limited’s EPS estimate?
              Daiichi Sankyo Company Limited’s EPS estimate is 39.78.
                How many shares outstanding does Daiichi Sankyo Company Limited have?
                Daiichi Sankyo Company Limited has 1,894,350,600 shares outstanding.
                  What happened to Daiichi Sankyo Company Limited’s price movement after its last earnings report?
                  Daiichi Sankyo Company Limited reported an EPS of ¥24.52 in its last earnings report, missing expectations of ¥44.829. Following the earnings report the stock price went down -4.503%.
                    Which hedge fund is a major shareholder of Daiichi Sankyo Company Limited?
                    Currently, no hedge funds are holding shares in JP:4568
                    What is the TipRanks Smart Score and how is it calculated?
                    Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

                      Company Description

                      Daiichi Sankyo Company Limited

                      Daiichi Sankyo Company, Limited (TSE: 4568) is a global pharmaceutical company headquartered in Tokyo, Japan. Established in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, the firm focuses on the research, development, manufacture, and marketing of innovative pharmaceuticals, primarily in the areas of oncology, cardiovascular diseases, and vaccines. Daiichi Sankyo is also involved in the development of generic drugs and biosimilars, offering a wide range of healthcare solutions to meet the needs of patients worldwide.

                      Daiichi Sankyo Company (4568) Earnings & Revenues

                      4568 Company Deck

                      4568 Earnings Call

                      Q2 2025
                      0:00 / 0:00
                      Earnings Call Sentiment|Positive
                      The earnings call presented a robust financial performance with significant revenue and profit growth, driven by strong product sales and successful patent settlements. However, slight downward adjustments in sales forecasts and potential financial uncertainties were noted.View all JP:4568 earnings summaries

                      4568 Stock 12 Month Forecast

                      Average Price Target

                      ¥5,801.28
                      ▲(73.64% Upside)
                      {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3279":"¥3,279","4840":"¥4,840","6401":"¥6,401","4059.5":"¥4,059.5","5620.5":"¥5,620.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6400.996729602176,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥6K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5801.2770597575,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥5.80K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4700.731973301598,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥4.70K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3279,4059.5,4840,5620.5,6401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3818,4016.692056123244,4215.384112246488,4414.076168369733,4612.768224492977,4811.460280616222,5010.152336739466,5208.84439286271,5407.536448985955,5606.2285051091985,5804.920561232443,6003.612617355688,6202.304673478931,{"y":6400.996729602176,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3818,3970.5597738275,4123.119547655,4275.6793214825,4428.23909531,4580.7988691375,4733.358642965,4885.9184167925,5038.4781906200005,5191.0379644475,5343.597738275001,5496.1575121025,5648.71728593,{"y":5801.2770597575,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3818,3885.9024594847383,3953.8049189694766,4021.707378454215,4089.609837938953,4157.512297423692,4225.41475690843,4293.317216393169,4361.219675877906,4429.122135362645,4497.024594847383,4564.927054332122,4632.82951381686,{"y":4700.731973301598,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4773.633,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4775.594,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4266.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3379.485,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3679.618,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3612.411,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3771.535,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3280.326,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3635.143,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3523.459,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3380,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3669,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3818,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Astellas Pharma
                      Chugai Pharmaceutical Co
                      Otsuka Holdings Co
                      Shionogi & Co
                      Takeda Pharmaceutical Co

                      Options Prices

                      Currently, No data available
                      ---
                      Popular Stocks